Buy Liquidia into 2026: FDA Approval, Early Uptake and a Clear Path to Revenue Growth
Liquidia (LQDA) enters 2026 as a small-cap commercial-stage biotech with an approved inhaled treprostinil (YUTREPIA) for PAH and PH-ILD, recent favorable litigation outcomes and early clinical readouts supporting adoption. The balance sheet and high valuation demand disciplined sizing, but the combination of label expansion, clinical data, and an a…